MRO Magazine

Global Proprotein Convertase Subtilisin Kexin 9 (PCSK-9) Inhibitors Pipeline Insights Report 2016 – Research and Markets


July 8, 2016
By Business Wire News

DUBLIN

Research and Markets has announced the addition of the “Proprotein Convertase Subtilisin Kexin 9 (PCSK-9) Inhibitors – Pipeline Insights, 2016” report to their offering.

Proprotein Convertase Subtilisin Kexin 9 (PCSK-9) Inhibitors-Pipeline Insights, 2016 provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under the category of Proprotein Convertase Subtilisin Kexin 9 (PCSK-9) Inhibitors.

Report Highlights:

– The new report, provides a Proprotein Convertase Subtilisin Kexin 9 (PCSK-9) Inhibitors Landscape across the globe

– The report provides drug profiles which includes product description, MOA, licensors & collaborators, development partner and chemical information

– Comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, Preclinical and Discovery stages

– Coverage of the Proprotein Convertase Subtilisin Kexin 9 (PCSK-9) Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type

– The report reviews key players involved in the therapeutics development for PCSK-9 Inhibitors and also provide company profiling

– Pipeline products coverage based on various stages of development from NDA filings to discovery.

– Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type.

Key Topics Covered:

  1. Overview
  2. Epidemiology
  3. Market Scenario
  4. Pipeline Therapeutics
  5. An Overview of Pipeline Products for PCSK-9 Inhibitors
  6. Therapeutics under Development by Companies
  7. Late Stage Products (Filed and Phase III)
  8. Comparative Analysis
  9. Mid Stage Products (Phase II)
  10. Comparative Analysis
  11. Product Description
  12. Product Development Activities
  13. Early Stage Products (Phase I and IND)
  14. Comparative Analysis
  15. Discovery and Pre-clinical stage Products
  16. Comparative Analysis
  17. Therapeutic Assessment
  18. Assessment by Monotherapy Products
  19. Assessment by Combination Products
  20. Assessment by Route of Administration
  21. Assessment by Molecule Type
  22. Discontinued Products
  23. Dormant Products
  24. Companies involved in Therapeutics Development

– Pfizer

– Serometrix

– Bristol-Myers Squibb/Ionis

– Shifa Biomedical

For more information visit http://www.researchandmarkets.com/research/2xn2wd/proprotein

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Enzymes, Food Additive Chemicals